STHLM3 NorDCaP:Stockholm3用于主动监测活检指导的前瞻性多中心试验
该前瞻性多中心试验纳入199例接受主动监测的ISUP GG1前列腺癌男性,在监测活检前进行Stockholm3检测。36%的患者出现ISUP升级。Stockholm3预测升级的AUC为0.71,阈值≥15时敏感性0.93、NPV 0.87,可减少19%的活检并漏诊5例升级(其中无ISUP≥3)。结论认为Stockholm3可能优化风险分层并减少不必要活检。
要点
- Stockholm3预测主动监测中前列腺癌ISUP升级的AUC为0.71。
- 阈值≥15时敏感性0.93,可减少19%活检,漏诊7%升级但无ISUP≥3。
- PSAD和mpMRI表现与Stockholm3相当,Stockholm3可作为血液互补工具。
核心结论
- 在低危前列腺癌主动监测男性中,Stockholm3可能增强风险分层并减少不必要的活检。
- Stockholm3与PSAD和mpMRI性能相当,可作为多模式策略中实用的血液补充工具。
研究设计与样本
- 前瞻性多中心试验STHLM3-AS NorDCaP纳入199例ISUP GG1前列腺癌主动监测男性,来自瑞典、丹麦和挪威(2019-2022)。
- 所有男性在监测活检前接受Stockholm3检测,主要结局为ISUP升级至GG2或更高。
主要发现
- 199例中72例(36%)在监测活检时升级。
- 升级者中位Stockholm3为35(IQR 26-50),未升级者为23(IQR 14-34),P < 0.01。
- Stockholm3的AUC为0.71(95%CI 0.64-0.79)。
- 阈值≥15时敏感性0.93(95%CI 0.85-0.98)、特异性0.26(95%CI 0.19-0.35)、NPV 0.87(95%CI 0.72-0.96),减少19%活检,漏诊5例(7%升级),无ISUP GG≥3。
- 阈值≥11时敏感性0.99(95%CI 0.93-1.00)、特异性0.11(95%CI 0.06-0.18)、NPV 0.93(95%CI 0.68-1.00)。
关键数值与推荐
- Stockholm3阈值≥15:敏感性0.93、特异性0.26、NPV 0.87,减少19%活检。
- Stockholm3阈值≥11:敏感性0.99、特异性0.11、NPV 0.93。
- PSAD阈值≥0.15:敏感性0.60、特异性0.72、NPV 0.75、AUC 0.71。
- PI-RADS阈值≥3:敏感性0.92、特异性0.33、NPV 0.84、AUC 0.72。
临床怎么用
- 对主动监测中ISUP GG1前列腺癌男性,可考虑使用Stockholm3辅助决定是否进行监测活检。
- Stockholm3阈值≥15可减少约19%活检且漏诊升级中无ISUP≥3,但需结合PSAD和mpMRI综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Active surveillance (AS) is the preferred approach for low-risk prostate cancer (PCa). Recent efforts have explored new biomarkers to reduce the frequency of surveillance biopsy. This study assessed Stockholm3 for predicting PCa upgrading during surveillance biopsies. MATERIALS AND METHODS: The prospective STHLM3-AS NorDCaP trial included 199 men with International Society of Urological Pathologists grade group 1 (ISUP GG 1) PCa under AS in Sweden, Denmark, and Norway (2019-2022). All men had ISUP GG 1 PCa and received a Stockholm3 test before surveillance biopsies. The primary outcome was ISUP upgrading, defined as ISUP GG 2 or higher. RESULTS: At surveillance biopsy, 72 of the 199 (36%) men were upgraded. Men with upgraded PCa had higher median Stockholm3 (35; interquartile range [IQR] 26-50) than those without upgrading (23; IQR 14-34, P < 0.01). The area under the receiver operating characteristic curve (AUC) for Stockholm3 was 0.71 (95% confidence interval [CI] 0.64-0.79). For Stockholm3 ≥15, sensitivity, specificity, and negative-predictive value (NPV) were 0.93 (95% CI 0.85-0.98), 0.26 (95% CI 0.19-0.35), and 0.87 (95% CI 0.72-0.96), respectively, sparing 19% of biopsies while missing five cases (7% of upgrades), none of which were ISUP GG ≥3. At a lower threshold (≥11), sensitivity increased to 0.99 (95% CI 0.93-1.00) with lower specificity (0.11; 95% CI 0.06-0.18) and an NPV of 0.93 (95% CI 0.68-1.00). Prostate-specific antigen density ≥0.15 showed a sensitivity of 0.60 (95% CI 0.48-0.72), specificity of 0.72 (95% CI 0.63-0.80), and NPV of 0.75 (95% CI 0.66-0.83), with an AUC of 0.71 (95% CI 0.63-0.79). Prostate Imaging-Reporting and Data System score ≥3 demonstrated a sensitivity of 0.92 (95% CI 0.83-0.97), specificity of 0.33 (95% CI 0.22-0.44), and NPV of 0.84 (95% CI 0.66-0.95), with an AUC of 0.72 (95% CI 0.65-0.79). CONCLUSION: In men with low-risk PCa under AS, Stockholm3 may enhance risk stratification and reduce unnecessary biopsies. Prostate-specific antigen density and multiparametric magnetic resonance imaging showed comparable performance, with Stockholm3 providing a potentially practical blood-based complement in a multimodal strategy.
引用
- Giudici N, Scuderi S, Palsdottir T, et al. STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance. BJU Int. 2026. PMID: 42383465. doi:10.1111/bju.70366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。